Faculty

John A. Thompson, MD

John A. Thompson, MD

Director, Phase 1 Medical Oncology
Department of Medicine
Division of Oncology

Mailing Address

Seattle Cancer Care Alliance
825 Eastlake Ave E, CE2-128
Seattle, WA 98109-1023


Admin Contact

Carly Zipper
206-606-1603
czipper@seattlecca.org

Specialty / Expertise

Melanoma and Renal Cancer

Research Interests

  • Director, Phase 1 Clinical Trials Program, UW/FHCRC
  • Immunotherapy
  • Activated lymphocytes and cytokines

Current Research Projects

Phase 1 study of PF-04518600 (OX40 mAb) with or without PF-05082566 (41BB mAb) for solid tumors.

Phase 1a/1b study of FPA008-003 (CSF1R mAb) with nivolumab for advanced cancers (NSCLC, Melanoma, SCCHN, Pancreatic, Colorectal, GMB, and Anaplastic Thyroid).

Phase 1 trial of TTI-621 (CD47 blocking protein) in subjects with percutaneously-accessible solid tumors and mycosis fungoides.

Phase 1/1b study of NIZ985 (hetIL-15) alone and with PDR001 (PD-1 mAb) for metastatic cancers (GI, GU, GYN, sarcoma and RCC).

Phase 2 study of AGS 163F (ADC) vs axitinib for renal cell carcinoma.

Phase 1/2 study of pembrolizumab + PEG-IFN and pembrolizumab + ipilimumab in subjects with melanoma and renal cell carcinoma.

Phase 1/1b study of CPI-444 (inhibitor of adenosine-2A receptor) w/ or w/o atezolizumab for select cancers (NSCLC, MEL, RCC, TNBC, mCRPC, Head & Neck, mCRC, bladder).

Adjuvant immunotherapy with anti-CTLA-4 monoclonal antibody (ipilimumab) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, double-blind Phase 3 trial of the EORTC Melanoma Group.

An open-label, extension (rollover) study of vemurafenib in patients with BRAFV600 mutation-positive malignancies previously enrolled in an antecedent vemurafenib protocol.

Expanded Access Program with Nivolumab (BMS-936558) in Combination with Ipilimumab (Yervoy) in Subjects with unresectable or metastatic melanoma.

Training

Dr. Thompson received his MD from University of Alabama, Birmingham, AL. He completed his Internal Medicine Residency at the University of Washington, Seattle, WA. He was a Post-Doctoral Fellow in Oncology at the University of Washington, Seattle, WA.

Selected Publications

Frankel AE, Flaherty KT, Weiner GJ, Chen R, Azad NS, Pishvaian MJ,Thompson JA, Taylor MH, Mahadevan D, Lockhart CA et al.. 2017. Academic Cancer Center Phase I Program Development.. The oncologist.

Paulson KG, Thompson JA. 2017. A second chance for success with BRAF and MEK inhibitors in melanoma.. The Lancet. Oncology.

Long GV, Atkinson V, Cebon JS, Jameson MB, Fitzharris BM, McNeil CM, Hill AG, Ribas A, Atkins MB, Thompson JA et al.. 2017. Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.. The Lancet. Oncology.

Chapuis AG, Roberts IM, Thompson, JA, Margolin KA, Bhatia S, Lee SM, Sloan HL, Lai IP, Farrar EA, Wagener F et al.. 2016. T-Cell Therapy Using Interleukin-21-Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 34(31):3787-3795.

Thompson, J.A., 2016. Major Changes in Systemic Therapy for Advanced Melanoma.. Journal of the National Comprehensive Cancer Network : JNCCN. 14(5 Suppl):638-40.

Chapuis AG, Lee SM, Thompson, JA , Roberts IM, Margolin KA, Bhatia S, Sloan HL, Lai I, Wagener F, Shibuya K et al.. 2016. Combined IL-21-primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient.. The Journal of experimental medicine. 213(7):1133-9.

Rodler ET, Kurland BF, Griffin M, Gralow JR, Porter P, Yeh RF, Gadi VK, Guenthoer J, Beumer JH, Korde L et al.. 2016. Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer.. Clinical cancer research : an official journal of the American Association for Cancer Research. 22(12):2855-2864.

Coit DG, Thompson, JA, Algazi A, Andtbacka R, Bichakjian CK, Carson WE, Daniels GA, Dimaio D, Fields RC, Fleming MD et al.. 2016. NCCN Guidelines Insights: Melanoma, Version 3.2016.. Journal of the National Comprehensive Cancer Network : JNCCN. 14(8):945-58.

Bhatia S, Pavlick AC, Boasberg P, Thompson JA , Mulligan G, Pickard MD, Faessel H, Dezube BJ, Hamid O. 2016. A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma.. Investigational new drugs.

Bono P, Oudard S, Bodrogi I, Hutson TE, Escudier B, Machiels J-P, Thompson JA, Figlin RA, Ravaud A, Basaran M et al.. 2016. Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials.. Clinical genitourinary cancer.

Bhatia S, Thompson JA. 2016. PD-1 Blockade in Melanoma: A Promising Start, but a Long Way to Go.. JAMA. 315(15):1573-5.

Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L, Berry S, Chartash EK, Daud A, Fling SP et al.. 2016. PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.. The New England journal of medicine.

Coit DG, Thompson JA, Algazi A, Andtbacka R, Bichakjian CK, Carson WE, Daniels GA, Dimaio D, Ernstoff M, Fields RC et al.. 2016. Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology.. Journal of the National Comprehensive Cancer Network : JNCCN. 14(4):450-73.

Last updated: August 2017

Top